Acute Myeloid Leukemia: An Ever-Changing Disease
Nancy M. Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-C
Ballad Health, Johnson City, Tennessee, and MD Anderson Cancer Center, Houston, Texas
Authors’ disclosures of potential conflicts of interest are found at the end of this article.
Allyson Price, MPAS, PA-C, 1515 Holcombe Boulevard, Houston, TX 77030. E-mail: firstname.lastname@example.org
© 2019 Harborside™
Acute myeloid leukemia is the most common form of acute leukemia in adults. In recent years, there has been robust characterization of molecular targets for drug development, leading to the U.S. Food & Drug Administration approval of numerous new treatments during 2017 and 2018. In light of these new approvals, this article provides an update for advanced practitioners on risk stratification, which is critical for guiding treatment selection.
This article is a part of a JADPRO certified supplement, Optimizing Treatment and Improving Outcomes for Patients With Acute Myeloid Leukemia: A Guide for Advanced Practitioners
Table of Contents
- Acute Myeloid Leukemia: An Ever-Changing Disease (current article)
- Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
- The Role of the Advanced Practitioner in Enhancing Outcomes
- Appendix: Key Information on Newly Approved AML Drugs
How to Earn Credit
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.
For access to the full length article, please sign in